158 related articles for article (PubMed ID: 24518705)
1. Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma.
El-Khalawany MA; Abou-Bakr AA
J Cancer Res Ther; 2013; 9(4):613-7. PubMed ID: 24518705
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Karahan N; Baspinar S; Bozkurt KK; Caloglu E; Ciris IM; Kapucuoglu N
Indian J Pathol Microbiol; 2011; 54(3):526-31. PubMed ID: 21934214
[TBL] [Abstract][Full Text] [Related]
3. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of ezrin in cutaneous basal and squamous cell carcinomas.
Abdou AG; Maraee AH; El-Sayed EM; Elnaidany NF
Ann Diagn Pathol; 2011 Dec; 15(6):394-401. PubMed ID: 21849257
[TBL] [Abstract][Full Text] [Related]
5. Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma.
Oh ST; Kim HS; Yoo NJ; Lee WS; Cho BK; Reichrath J
Br J Dermatol; 2011 Dec; 165(6):1197-204. PubMed ID: 21729023
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
[TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
8. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma.
Yerebakan O; Ciftçioglu MA; Akkaya BK; Yilmaz E
J Dermatol; 2003 Jan; 30(1):33-41. PubMed ID: 12598707
[TBL] [Abstract][Full Text] [Related]
10. The use of antidesmoglein stains in Mohs micrographic surgery. A potential aid for the differentiation of basal cell carcinoma from horizontal sections of the hair follicle and folliculocentric basaloid proliferation.
Krunic AL; Garrod DR; Viehman GE; Madani S; Buchanan MD; Clark RE
Dermatol Surg; 1997 Jun; 23(6):463-8. PubMed ID: 9217798
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of TIMP-3 and MMP-9 in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma.
Poswar FO; Fraga CA; Farias LC; Feltenberger JD; Cruz VP; Santos SH; Silveira CM; de Paula AM; Guimarães AL
Pathol Res Pract; 2013 Nov; 209(11):705-9. PubMed ID: 24011615
[TBL] [Abstract][Full Text] [Related]
12. Recurrent morphean basal cell carcinoma of the skin. A clinico-histopathological study of 97 cases.
Anthouli-Anagnostopoulou F; Hatziolou E
Adv Clin Path; 2002 Jan; 6(1):17-24. PubMed ID: 17582944
[TBL] [Abstract][Full Text] [Related]
13. The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer.
Fanelli MF; Chinen LT; Begnami MD; Costa WL; Fregnami JH; Soares FA; Montagnini AL
Histopathology; 2012 Aug; 61(2):153-61. PubMed ID: 22582975
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.
Nart D; Yaman B; Yilmaz F; Zeytunlu M; Karasu Z; Kiliç M
Liver Transpl; 2010 May; 16(5):621-30. PubMed ID: 20440771
[TBL] [Abstract][Full Text] [Related]
15. CD10 expression in trichoepithelioma and basal cell carcinoma.
Pham TT; Selim MA; Burchette JL; Madden J; Turner J; Herman C
J Cutan Pathol; 2006 Feb; 33(2):123-8. PubMed ID: 16420307
[TBL] [Abstract][Full Text] [Related]
16. Anti-cytokeratin 20 staining of Merkel cells helps differentiate basaloid proliferations overlying dermatofibromas from basal cell carcinoma.
Mahmoodi M; Asad H; Salim S; Kantor G; Minimo C
J Cutan Pathol; 2005 Aug; 32(7):491-5. PubMed ID: 16008693
[TBL] [Abstract][Full Text] [Related]
17. [Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance].
Luo CF; Zhu RQ; Wang H; Lu YL
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):526-30. PubMed ID: 18069634
[TBL] [Abstract][Full Text] [Related]
18. Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma.
Janisson-Dargaud D; Durlach A; Lorenzato M; Grange F; Bernard P; Birembaut P
J Cutan Pathol; 2008 Oct; 35(10):916-21. PubMed ID: 18537864
[TBL] [Abstract][Full Text] [Related]
19. Calcifications associated with basal cell carcinoma: prevalence, characteristics, and correlations.
Slodkowska EA; Cribier B; Peltre B; Jones DM; Carlson JA
Am J Dermatopathol; 2010 Aug; 32(6):557-64. PubMed ID: 20489568
[TBL] [Abstract][Full Text] [Related]
20. High recurrence rates of Basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukemia.
Mehrany K; Weenig RH; Pittelkow MR; Roenigk RK; Otley CC
Arch Dermatol; 2004 Aug; 140(8):985-8. PubMed ID: 15313816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
